| Name: |
Epoetin alpha |
|---|
| Synonyms: |
|
|---|
| Trade name: |
Epogen®, Procrit®[1], Ortho Biotech Products, L.P.; Bridgewater, NJ[2]
Neorecormon, Roche[3]
|
|---|
| Chemical name: |
|
|---|
| Molecular Weight: |
It has a molecular weight of 30,400 Da.[4]
|
|---|
| Source: |
|
| Structure: |
|
| Chemical Nature: |
It has three asparagine-linked carbohydrate chains and O-linked glycosylation sites.[5]
|
| Actions & Indications: |
Pharmcological Action-
Therapeutic indications:
Preclinical study-
|
| Notes: |
|
| REFERENCES |
| 1. |
Epogen/Procrit; In : Directory of Approved Biopharmaceutical Products by Spada S, Walsh G, CRC Press, 2004, page no. 39.
https://books.google.com.sg/books?id=CZaCXXVvirEC&pg=PA39 |
| 2. |
Shasha D, George MJ, Harrison LB, Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer. 2003 ;98(5):1072-9.
http://dx.doi.org/10.1002/cncr.11616 |
| 3. |
Nigro CL et al, Impact of erythropoietin (EPO) on irradiation effect on the
EPO receptor positive head and neck cancer. Can Res 2008;
68(9 Supplement).
http://cancerres.aacrjournals.org/content/68/9_Supplement/5771 |
| 4. |
15. Anabolic doping agent by von Deutsch DA et al; In : Handbook of Drug Interactions: A Clinical and Forensic Guide, 2nd edition, edited by Mozayani A, Raymon L, Springer Science & Business Media, 2011, page no. 726.
https://books.google.co.in/books?id=NhBJ6kg_uP0C&pg=PA726 |
| 5. |
Egrie JC et al, Characterization and biological effects of recombinant
human erythropoietin. Immunobiol. 1986;172(3-5):213-224.
http://dx.doi.org/10.1016/S0171-2985(86)80101-2 |
